8-K: Enhabit Reports Strong First Quarter 2025 Results, Exceeds Expectations

Enhabit, Inc. reports a successful first quarter in 2025, driven by census growth in both home health and hospice segments, improved profitability, and balance sheet improvements.

Summary

• Enhabit, Inc. reported its first quarter 2025 financial results, showcasing growth in both home health and hospice segments.
• Net service revenue reached $259.9 million.
• Net income attributable to Enhabit, Inc. was $17.8 million, including a gain on sale of investment of $14.7 million, net of tax.
• Adjusted EBITDA stood at $26.6 million.
• Earnings per share were reported at $0.35, with adjusted diluted earnings per share at $0.10.
• The company's home health census grew 3.7% sequentially, and hospice census grew 12.3% year over year.
• The leverage ratio is now below 4.5 times, allowing the company to exit the covenant relief period restrictions in its credit agreement.
• Enhabit reaffirmed its full-year 2025 guidance, projecting net service revenue between $1,050 and $1,080 million and adjusted EBITDA between $101 and $107 million.
• Adjusted EPS is projected between $0.41 and $0.51.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in key areas and improved financial performance. The company is exceeding expectations and has reaffirmed its full-year guidance.

Positives

• Home health non-Medicare admissions increased 7.4% year over year.
• Sequential home health Medicare ADC growth of 1.5%, marking the second consecutive quarter of growth.
• Total home health ADC sequential growth of 3.7% and exited Q1 2025 with ADC above prior year.
• Home health cost per patient day decreased 2.4% year over year.
• Hospice average daily census increased 12.3% year over year.
• Hospice admissions increased 8.0% year over year.
• One Hospice de novo branch opened in Q1.
• Reduced bank debt by $25.0 million in the quarter.
• Home office G&A expenses decreased 1.3% due to cost control initiatives.
• The company's clinical expertise and high-quality outcomes are better than the national average.

Negatives

• Home health net service revenue decreased by 5.9% year over year.
• Medicare admissions decreased 7.3% year over year.
• Total home health admissions growth was only 0.7% year over year, although it was 2.5% when normalizing for leap year and branches closed in Q1.
• Home health visits decreased 9.4% year over year.

Risks

• Regulatory and other developments impacting the markets for our services could adversely affect Enhabit.
• Changes in reimbursement rates could impact revenue.
• General economic conditions could affect the demand for services.
• The company's ability to attract and retain key management personnel and healthcare professionals is crucial.
• Potential disruptions or breaches of information systems could harm operations.
• The outcome of litigation could have a financial impact.
• Quality performance and ratings could affect the company's reputation and reimbursement rates.
• The company's ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures is important for growth.
• The company's ability to successfully integrate technology in its operations is essential for efficiency.
• The company's ability to control costs, particularly labor and employee benefit costs, is critical for profitability.

Future Outlook

Enhabit reaffirmed its full-year 2025 guidance, projecting net service revenue between $1,050 and $1,080 million and adjusted EBITDA between $101 and $107 million. Adjusted EPS is projected between $0.41 and $0.51.

Management Comments

• Enhabit's first quarter 2025 results are a product of steadfast execution of our strategies, said Barb Jacobsmeyer, president and CEO of Enhabit.

Industry Context

The aging population and the cost-efficiency of home health and hospice care provide attractive industry tailwinds for Enhabit. The company operates in a large and growing addressable market, with Medicare skilled home health and hospice expenditures projected to reach ~$41 billion and ~$32 billion, respectively, by 2028.

Comparison to Industry Standards

• Enhabit's Quality of Patient Care (QoPC) Star Rating is 3.2, which is 6.7% better than the national average of 3.0.
• Enhabit's HHCAHPS Star Rating is 3.9, which is 5.4% better than the national average of 3.7.
• Enhabit's 30-Day Hospital Readmission Rate is 13.7%, which is 23.9% better than the national average of 18.0%.
• Enhabit's Patient Visits in Last Days of Life is 67.1%, which is 41.6% better than the national average of 47.4%.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and growth prospects.
• Employees will benefit from the company's award-winning culture and leadership development programs.
• Patients will benefit from the company's commitment to providing superior, cost-effective care in their homes.
• Health systems and payers will benefit from the company's high-quality outcomes and cost-efficiency.

Next Steps

• The company will host an investor conference call on May 8, 2025, to discuss its results for the first quarter of 2025.

Key Dates

Keywords

Enhabit, home health, hospice, financial results, EBITDA, census, revenue, earnings, admissions